Ovuloc Tablets

Ovuloc Tablets (Desogestrel and Ethinyl Estradiol Tablets) - Product Information

Ovuloc (Desogestrel and Ethinyl Estradiol tablets USP) blister cards provide an oral contraceptive regimen of 21 round tablets each containing 0.15 mg Desogestrel and 0.03 mg Ethinyl Estradiol. Ovuloc is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. It helps to prevent the release of the egg and its fertilization by the sperm. It may also help to reduce the risk of ovarian cancer. Besides preventing pregnancy, birth control pills may make your periods more regular, decrease blood loss and painful periods, decrease your risk of ovarian cysts, and also treat acne.
No contraceptive method is 100 percent effective. Discuss your options for birth control with your doctor.
This medicine does not prevent HIV infection or other sexually transmitted diseases. It will not help as emergency contraception, such as after unprotected sexual contact.
We also have in stock Yasmin contraceptive pill which protects against pregnancy as well as treats acne.

Presentation and Marketing of Ovuloc Tablets

Ovuloc Tablets are manufactured by Serum Institute of India Private Ltd and is offered to the consumer in a strip of 21 tablets.

Manufacturer of Ovuloc Tablets

Serum Institute of India Private Ltd. (In collaboration with Maneesh Pharmaceutical Ltd.)  
Website: www.seruminstitute.com

Active Ingredient present in Tablets

The active ingredient present in Ovuloc Tablets are Desogestrel and Ethinyl Estradiol Estradiol. Each tablet contains 150 mcg Desogestrel and 30 mcg Ethinyl Estradiol.

How Does Ovuloc Tablet Work?

Desogestrel and ethinyl estradiol combination is used to prevent pregnancy. It is a birth control pill that contains two types of hormones, Desogestrel and Ethinyl Estradiol, and when taken properly, prevents pregnancy. It works by stopping a woman's egg from fully developing each month. The egg can no longer accept a sperm and fertilization (pregnancy) is prevented.

Ovuloc Tablets - Dosage and Administration

Day 1 Start:
The dosage of Ovuloc for the initial cycle of therapy is one rose-colored “active” tablet administered daily from the 1st day through the 21st day of the menstrual cycle, counting the first day of menstrual flow as “Day 1”. Tablets are taken without interruption as follows: One rose-colored “active” tablet daily for 21 days, followed by 7 tablet free days. After which, a new course is started and a rose-colored “active” tablet is taken the next day.
The use of Ovuloc for contraception may be initiated 4 weeks postpartum in women who elect not to breastfeed. When the tablets are administered during the postpartum period, the increased risk of thromboembolic disease associated with the postpartum period must be considered.

Sunday Start
When taking Ovuloc, the first rose-colored “active” tablet should be taken on the first Sunday after menstruation begins. If the period begins on Sunday, the first rose-colored “active” tablet is taken on that day. If switching directly from another oral contraceptive, the first rose-colored “active” tablet should be taken on the first Sunday after the last ACTIVE tablet of the previous product. Tablets are taken without interruption as follows: One rose-colored “active” tablet daily for 21 days, followed by 7 tablet free days. After which, a new course is started and a rose-colored “active” tablet is taken the next day (Sunday).
When starting a Sunday start regimen, another method of contraception should be used until after the first 7 consecutive days of administration.
 

Ovuloc Tablets - Missed Pill Instructions;

If the patient misses one (1) rose-colored “active” tablet in Weeks 1, 2, or 3, the rose-colored “active” tablet should be taken as soon as she remembers.
If the patient misses two (2) rose-colored “active” tablets in Week 1 or Week 2, the patient should take two (2) rose-colored “active” tablets the day she remembers and two (2) rose-colored “active” tablets the next day; and then continue taking one (1) rose-colored “active” tablet a day until she finishes the pack.
The patient should be instructed to use a back-up method of birth control such as a condom or spermicide if she has sex in the seven (7) days after missing pills.
If the patient misses two (2) rose-colored “active” tablets in the third week or misses three (3) or more rose-colored “active” tablets in a row, the patient should throw out the rest of the pack and start a new pack that same day. The patient should be instructed to use a back-up method of birth control if she has sex in the seven (7) days after missing pills.

Ovuloc Tablets (Desogestrel and Ethinyl Estradiol Tablets) Tablets Contraindications

Ovuloc tablets should not be used in females who are known to have or develop the following conditions:
 

• Hypersensitivity to Desogestrel, Ethinyl Estradiol or to any of the inactive ingredients contained in Ovuloc tablets
• Thrombophlebitis or thromboembolic disorders
• A past history of deep vein thrombophlebitis or thromboembolic disorders
• Known thrombophilic conditions
• Cerebral vascular or coronary artery disease (current or history)
• Valvular heart disease with complications
• Persistent blood pressure values of > 160 mm Hg systolic or > 100 mg Hg diastolic
• Diabetes with vascular involvement
• Headaches with focal neurological symptoms
• Major surgery with prolonged immobilization
• Current diagnosis of, or history of, breast cancer, which may be hormone-sensitive
• Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia
• Undiagnosed abnormal genital bleeding
• Cholestatic jaundice of pregnancy or jaundice with prior pill use
• Acute or chronic hepatocellular disease with abnormal liver function
• Hepatic adenomas or carcinomas
• Known or suspected pregnancy
• Are receiving Hepatitis C drug combinations containing Ombitasvir/Paritaprevir/Ritonavir, with or without Dasabuvir, due to the potential for ALT elevations

Warnings and Precautions while on Ovuloc Tablets

Discontinue the medication at the Earliest Manifestation of:
A. Thromboembolic and cardiovascular disorders, such as thrombophlebitis, pulmonary embolism, cerebrovascular disorders, myocardial ischemia, mesenteric thrombosis, and retinal thrombosis.
B. Conditions which predispose to venous stasis and to vascular thrombosis (e.g., immobilization after accidents or confinement to bed during long-term illness). Other non-hormonal methods of contraception should be used until regular activities are resumed.
C. Visual defects - partial or complete.
D. Papilledema or ophthalmic vascular lesions.
E. Severe headache of unknown etiology or worsening of pre-existing migraine headache.
F. Increase in epileptic seizures
The use of Combined Oral Contraceptives is associated with increased risks of several serious conditions including myocardial infarction, thromboembolism, stroke, hepatic neoplasia and gallbladder disease, although the risk of serious morbidity and mortality is small in healthy women without underlying risk factors.

Overdosage

Serious ill effects have not been reported following acute ingestion of large doses of oral contraceptives by young children.
Overdosage may cause nausea, and withdrawal bleeding may occur in females.

Storage

Store Ovuloc tablets at controlled room temperature (59°F to 86°F, 15°C to 30°C). Protect from light. Keep in a safe place out of the reach of children and pets.

Side Effects of Tablets

The following side effects also have been reported in patients receiving combination hormonal contraceptives: nausea and vomiting, usually the most common adverse reaction, occurs in approximately 10% or fewer of patients during the first cycle.
An increased risk of the following serious adverse reactions has been associated with the use of combination hormonal contraceptives:

• arterial and venous thromboembolism
• benign and malignant hepatic tumours
• cerebral hemorrhage
• cerebral thrombosis
• congenital anomalies
• gallbladder disease
• hypertension
• mesenteric thrombosis
• myocardial infarction
• neuro-ocular lesions (e.g., retinal thrombosis)
• pulmonary embolism
• thrombophlebiti

Ovuloc Tablets During Pregnancy

Desogestrel and Ethinyl Estradiol Tablets (Ovuloc Tablets) have been classified by the US FDA as pregnancy category X. Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience.
Oral contraceptives should not be taken by pregnant women. If pregnancy occurs during treatment with Ovuloc, further intake should be stopped. However, if conception accidentally occurs while taking the pill, there is no conclusive evidence that the estrogen and progestin contained in the oral contraceptive will damage the developing child.

Nursing Considerations

In breast-feeding women, the use of oral contraceptives results in the hormonal components being excreted in breast milk and may reduce its quantity and quality.
Adverse effects on the child have been reported, including jaundice and breast enlargement. The nursing mother should be advised not to use oral contraceptives but to use other forms of contraception until she has completely weaned her child.

Buy Ovuloc Tablets Online at only $0.55 per Tablet

You can buy Desogestrel and Ethinyl Estradiol tablets online from all contraceptives. Ovuloc birth control pills, manufactured by Serum Institute of India Private Ltd., are supplied in a blister strip of 21 tablets. The tablets containing cost only $0.55 per unit when you place an order for 252 tablets.

Shipping Restriction